Wire · opportunities
RYBREVANT FASPRO combination demonstrates 77% overall response rate in first-line ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 25 October 2026 · Fusion42 review
Johnson & Johnson announced that the RYBREVANT FASPRO combination achieved a 77% overall response rate in first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), excluding HPV-associated types. The treatment showed deep, durable tumor responses and supports ongoing Phase 3 trials and regulatory review.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You can now explore combining EGFR and MET targeting in head and neck cancer earlier in treatment to improve patient outcomes. The strong results open doors for faster Phase 3 trial advancement and new market opportunities.
◆ Coverage
1 source · 25 Oct 2026
◆ Related on Wire
◆ Topics